Effects of lorglumide on growth and invasion of human pancreatic cancer cell line Mia PaCa-2 in vitro through the cholecystokinin-cholecystokinin-1 receptor pathway

Current Therapeutic Research - Clinical and Experimental

Volumn 71, Issue 4, 2010, Pages 239-251

  Zhou, Jin ^a   Zhang, Zi Xiang ^a   Li, De Chun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Apoptosis; CCK 1 receptor; Cholecystokinin; MMP 2; Pancreatic cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CHOLECYSTOKININ; CHOLECYSTOKININ 8S; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR 1; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; DNA NUCLEOTIDYLEXOTRANSFERASE; GELATINASE A; LORGLUMIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 77958534247     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2010.08.005     Document Type: Article

References (32)

1. Chua YJ, Zalcberg JR Pancreatic cancer-is the wall crumbling?. Ann Oncol. 2008, 19:1224-1230.
2. Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: Meta-analysis of randomized conrrolled rrials. Arch Surg. 2008, 143:75-83. Pancreatic Cancer Meta-Analysis Group, discussion 83.
3. Jimeno A, Hidalgo M Molecular biomarkers: Their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther. 2006, 5:787-796.
4. Fournier A, Boutron-Ruault MC, Clavel-Chapelon F Breast cancer and hormonal therapy in postmenopausal women. N Engl J Med. 2009, 360:2366. author reply 2366-2367.
5. Van Allen EM, Ryan CJ Novel secondary hormonal therapy in advanced prostate cancer: An update. Curr Opin Urol. 2009, 19:315-321.
6. Woyach JA, Shah MH New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer. 2009, 16:715-731.
7. Barrington E, Dockray G Gastroinrestinal hormones. J Endocrinol. 1976, 69:299-325.
8. Wank SA G protein-coupled receptors in gasrrointestinal physiology. I. CCK receptors: An exemplary family. Am J Physiol. 1998, 274:G607-G613.
9. Baldwin GS, Shulkes A CCK receptors and cancer. Curr Top Med Chem. 2007, 7:1232-1238.
10. Cheng ZJ, Harikumar KG, Ding WQ, et al. Analysis of the cellular and molecular mechanisms of trophic action of a misspliced form of the type B cholecystokinin receptor present in colon and pancreatic cancer. Cancer Lett. 2005, 222:95-105.
11. Cayrol C, Clerc P, Berrrand C, et al. Cholecystokinin-2 receptor modulates cell adhesion through beta 1-integrin in human pancreatic cancer cells. Oncogene. 2006, 25:4421-4428.
12. Kobayashi N, Seto K, Orikawa Y, et al. Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells. Biol Pharm Bull. 2010, 33:216-222.
13. Kawasaki D, Emori Y, Eta R, et al. Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonisr on rumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action detetminations in vitro. Cancer Chemother Pharmacol. 2008, 61:883-892.
14. Nock BA, Maina T, Béhé M, et al. CCK-2/gastrin receptor-targeted tumor imaging with (99m) Tc-labeled minigastrin analogs. J Nucl Med. 2005, 46:1727-1736.
15. Savage K, Waller HA, Srubbs M, et al. Targeting of cholecystokinin B/gastfin receptor in colonic, pancreatic and hepatocellular carcinoma cell lines. Int J Oncol. 2006, 29:1429-1435.
16. Moonka R, Zhou W, Bell RH Cholecystokinin-A receptor messenger RNA expression in human pancreatic cancer. J Gastrointest Surg. 1999, 3:134-140.
17. Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review. J Clin Oncol. 2009, 27:2269-2277.
18. Pan XT, Zhu QY, Li DC, et al. Effect of recombinant adenovirus vecror mediared human interleukin-24 gene transfection on pancreatic carcinoma growth. Chin Med J (Engl). 2008, 121:2031-2036.
19. Reubi J Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003, 24:389-427.
20. Brooks FP The neurohumoral control of pancreatic exocrine secretion. Am J Clin Nutr. 1973, 26:291-310.
21. Andrén-Sandberg A, Hoem D, Bäckman PL Other risk factors for pancreatic cancer: Hormonal aspects. Ann Oncol. 1999, 10(Suppl 4):131-135.
22. Kobelt P, Paulitsch S, Goebel M, et al. Peripheral injection of CCK-8S induces Fos expression in the dorsomedial hypothalamic nucleus in rats. Brain Res. 2006, 1117:109-117.
23. Colucci R, Blandizzi C, Tanini M, et al. Gastrin promotes human colon cancer cell growth via CCK-2 receptor-mediated cyclooxygenase-2 induction and prostaglandin E2 production. Br J Pharmacol. 2005, 144:338-348.
24. Archer-Lahlou E, Escrieut C, Clerc P, et al. Molecular mechanism underlying partial and full agonism mediated by the human cholecystokinin-1 receptor. J Biol Chem. 2005, 280:10664-10674.
25. Elmore S Apoptosis: A review of programmed cell death. Toxicol Pathol. 2007, 35:495-516.
26. Reubi JC Targeting CCK receptors in human cancers. Curr Top Med Chem. 2007, 7:1239-1242.
27. González-Puga C, García-Navarro A, Escames G, et al. Selective CCK-A but not CCK-B receptor antagonists inhibit HT-29 cell proliferation: Synergism with pharmacological levels of melatonin. J Pineal Res. 2005, 39:243-250.
28. Lu Y, Bai JG, Wang HH Gene therapeutic treatment of pancreatic cancer based on injection of pcDNA3.1/CCK plasmid with xenogeneic homologous cholecystokinin. Exp Oncol. 2006, 28:136-140.
29. Berna MJ, Tapia JA, Sancho V, Jensen RT Progress in developing cholecystokinin (CCK)/ gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol. 2007, 7:583-592.
30. Li Z, Ding Q, Li Y, Miller SA, et al. Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant. Cancer Lett. 2006, 236:58-63.
31. Määttä M, Soini Y, Liakka A, Autio-Harmainen H Differential expression of matrix metallo-proteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: Implications for tumor progression and clinical prognosis. Clin Cancer Res. 2000, 6:2726-2734.
32. Juuti A, Lundin J, Nordling S, et al. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer. Oncology. 2006, 71:61-68.